**Appendix 2**

**Sensitivities in women who underwent LEEP and where the LEEP diagnosis was used as the gold standard and corresponding 2x2 tables**

|  |  |  |
| --- | --- | --- |
|  | Sensitivity of DSI colposcopy | Sensitivity of conventional colposcopy |
| Biopsy 1: CDB | 81.9%(74.1–88.2) | 71.4%(61.4–80.1) |
| Biopsy 2 | 81.1%(73.2–87.5) | 63.3%(52.9–72.8) |
| DSI-directed biopsyi.e., worst area indicated by the DSI map\* | 85.8%(78.5–91.4) | NA |
| Combination of CDB and DSI\*\* | 89.0%(82.2–93.8) | NA |
| Biopsy 3 | 64.6%(55.6–72.8) | 69.4%(59.3–78.3) |
| Biopsy 4 | 60.6%(51.6–69.2) | 65.3%(55.0–74.6) |
| Biopsy 1+2 | 95.3%(90.0–98.3) | 84.7%(76.0–91.2) |
| Biopsy 1+2+3 | 98.4%(94.4–99.8) | 92.9%(85.8–97.1) |
| Biopsy 1+2+3+4 | 99.2%(95.6–99.9) | 100.0%(96.3–100.0) |

**Dynamic spectral imaging group**

**Colposcopy directed biopsy (CDB) diagnosis versus LEEP diagnosis**

**1. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **CDB** | CIN2+ | <CIN2 |
| CIN2+ | 104 | 1 |
| <CIN2 | 23 | 5 |

**DSI directed biopsy diagnosis versus LEEP diagnosis**

**2. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **DSI** | CIN2+ | <CIN2 |
| CIN2+ | 109 | 0 |
| <CIN2 | 18 | 6 |

**DSI directed biopsy and CDB combined diagnosis versus LEEP diagnosis**

**3. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **CDB+DSI** | CIN2+ | <CIN2 |
| CIN2+ | 113 | 1 |
| <CIN2 | 14 | 5 |

**Biopsy no. 2 diagnosis versus LEEP diagnosis**

**4. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.2**  | CIN2+ | <CIN2 |
| CIN2+ | 103 | 3 |
| <CIN2 | 24 | 3 |

**Biopsy no. 3 diagnosis versus LEEP diagnosis**

**5. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.3**  | CIN2+ | <CIN2 |
| CIN2+ | 82 | 2 |
| <CIN2 | 45 | 4 |

**Biopsy no. 4 diagnosis versus LEEP diagnosis**

**6. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.4**  | CIN2+ | <CIN2 |
| CIN2+ | 77 | 1 |
| <CIN2 | 50 | 5 |

**Combined diagnosis of biopsy no. 1 and 2 versus LEEP diagnosis**

**7. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2**  | CIN2+ | <CIN2 |
| CIN2+ | 121 | 4 |
| <CIN2 | 6 | 2 |

**Combined diagnosis of biopsy no. 1, 2 and 3 versus LEEP diagnosis**

**8. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2+3**  | CIN2+ | <CIN2 |
| CIN2+ | 125 | 5 |
| <CIN2 | 2 | 1 |

**Combined diagnosis of biopsy no. 1, 2, 3 and 4 versus LEEP diagnosis**

**9. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2+3 +4**  | CIN2+ | <CIN2 |
| CIN2+ | 126 | 5 |
| <CIN2 | 1 | 1 |

**Regular Colposcopy group**

**Colposcopy directed biopsy (CDB) diagnosis versus LEEP diagnosis**

**10. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **CDB** | CIN2+ | <CIN2 |
| CIN2+ | 70 | 0 |
| <CIN2 | 28 | 3 |

**Biopsy no. 2 diagnosis versus LEEP diagnosis**

**11. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.2**  | CIN2+ | <CIN2 |
| CIN2+ | 62 | 1 |
| <CIN2 | 36 | 2 |

**Biopsy no. 3 diagnosis versus LEEP diagnosis**

**12. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.3**  | CIN2+ | <CIN2 |
| CIN2+ | 68 | 1 |
| <CIN2 | 30 | 2 |

**Biopsy no. 4 diagnosis versus LEEP diagnosis**

**13. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.4**  | CIN2+ | <CIN2 |
| CIN2+ | 64 | 0 |
| <CIN2 | 34 | 3 |

**Combined diagnosis of biopsy no. 1 and 2 versus LEEP diagnosis**

**14. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2**  | CIN2+ | <CIN2 |
| CIN2+ | 83 | 1 |
| <CIN2 | 15 | 2 |

**Combined diagnosis of biopsy no. 1, 2 and 3 versus LEEP diagnosis**

**15. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2+3**  | CIN2+ | <CIN2 |
| CIN2+ | 91 | 2 |
| <CIN2 | 7 | 1 |

**Combined diagnosis of biopsy no. 1, 2, 3 and 4 versus LEEP diagnosis**

**16. All women**

|  |  |
| --- | --- |
|  | **Final** |
| **no.1+2+3 + 4**  | CIN2+ | <CIN2 |
| CIN2+ | 98 | 2 |
| <CIN2 | 0 | 1 |